🤑 It doesn’t get more affordable. Grab this 60% OFF Black Friday offer before it disappears…CLAIM SALE

Cencora executive chairman Steven Collis sells $12.2 million in stock

Published 11/26/2024, 04:37 PM
COR
-

Steven H. Collis, Executive Chairman of Cencora, Inc. (NYSE:COR), recently sold 50,000 shares of the company's common stock. The shares were sold at a weighted average price of $243.98 per share, totaling approximately $12.2 million. Following the transaction, Collis retains ownership of 326,556.665 shares.

In a separate transaction, Collis donated 4,644 shares to a donor-advised fund for charitable purposes. This donation did not involve any cash consideration and left Collis with 321,912.665 shares.

In other recent news, healthcare solutions provider Cencora has reported robust growth in its fiscal 2024 fourth quarter, noting a 15% increase in adjusted earnings. The company also announced the acquisition of Retina Consultants of America (RCA), a move expected to align with its strategic focus and enhance its MSO solutions. The company's Q4 adjusted diluted EPS rose by 17% year-over-year to $3.34, while consolidated revenue increased by 15% to $79.1 billion. The company's US Healthcare Solutions segment saw a revenue increase of 16%, driven by a 55% surge in GLP-1 product sales. Looking ahead, Cencora's fiscal 2025 guidance projects an adjusted diluted EPS between $14.80 and $15.10 and revenue growth of 7% to 9%. The acquisition of RCA is expected to contribute approximately $0.35 in its first year. Despite a 9% drop in operating income for the International Healthcare Solutions segment, the company remains optimistic about future growth.

InvestingPro Insights

To provide additional context to Steven H. Collis's recent stock transactions, let's examine some key financial metrics and insights from InvestingPro for Cencora, Inc. (NYSE:COR).

As of the latest data, Cencora boasts a substantial market capitalization of $48.65 billion, reflecting its significant presence in the Healthcare Providers & Services industry. The company's stock is currently trading near its 52-week high, with a price that is 98.76% of its peak, indicating strong market performance.

Cencora's financial health appears robust, with revenue growth of 12.12% over the last twelve months and an impressive 14.69% growth in the most recent quarter. This growth trajectory aligns with the company's status as a prominent player in its sector.

InvestingPro Tips highlight that Cencora has maintained dividend payments for 24 consecutive years and has raised its dividend for 20 consecutive years. This consistent dividend history suggests a strong commitment to shareholder returns, which may be attractive to income-focused investors.

However, it's worth noting that the stock is trading at a relatively high P/E ratio of 32.59, which could indicate that the market has high expectations for future growth. Additionally, InvestingPro Tips point out that the company suffers from weak gross profit margins, which stood at 3.39% for the last twelve months.

For investors seeking a more comprehensive analysis, InvestingPro offers 17 additional tips for Cencora, providing a deeper understanding of the company's financial position and market outlook.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.